Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
OncoGenex Technologies Inc in collaboration with Isis Pharmaceuticals Inc is developing OGX-011, an intravenously administered clusterin-inhibiting antisense oligonucleotide, to potentially sensitize solid tumors that are resistant to conventional cancer therapeutics. Phase II clinical trials of OGX-011 in combination with chemotherapeutic drugs are underway in NSCLC, prostate and breast cancer.